Harvard Bioscience, Inc. (NASDAQ: HBIO) Executes Reverse Stock Split

Harvard Bioscience, Inc. (NASDAQ: HBIO) is a key player in the life science research tools sector. The company provides essential equipment and solutions for scientific research, supporting advancements in biology and medicine. HBIO competes with other companies in the life sciences industry, striving to maintain its position through innovation and strategic decisions.

On March 16, 2026, HBIO executed a reverse stock split at a 10-for-1 ratio. This move, approved by the board and stockholders, aims to boost the stock's per-share trading price. The reverse split is a strategic effort to meet the Nasdaq Capital Market's minimum bid price requirement, ensuring HBIO's continued listing.

The reverse stock split legally took effect on March 13, 2026, at 4:30 p.m. Eastern Time. HBIO's stock began trading on a post-split adjusted basis on March 16, 2026. This adjustment is crucial for maintaining investor confidence and market presence.

Currently, HBIO's stock is priced at $0.47, reflecting a 4.15% decrease with a $0.02 change. The stock has fluctuated between $0.45 and $0.49 yesterday. Over the past year, it reached a high of $9.45 and a low of $0.45, indicating significant volatility.

HBIO's market capitalization stands at approximately $21.17 million, with a trading volume of 479,292 shares. These figures highlight the company's market activity and investor interest, crucial for its strategic growth and stability.